Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the neurological sciences 2020-05, Vol.412, p.116803-116803, Article 116803
Hauptverfasser:	Jacob, Saiju, Muppidi, Srikanth, Guidon, Amanda, Guptill, Jeffrey, Hehir, Michael, Howard, James F., Illa, Isabel, Mantegazza, Renato, Murai, Hiroyuki, Utsugisawa, Kimiaki, Vissing, John, Wiendl, Heinz, Nowak, Richard J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Betacoronavirus Clinical Trials as Topic Coronavirus Infections - complications Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Disease Management Disease Susceptibility Humans Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Immunosuppressive Agents - therapeutic use Immunotherapy Lambert-Eaton Myasthenic Syndrome - complications Lambert-Eaton Myasthenic Syndrome - drug therapy Lambert-Eaton Myasthenic Syndrome - therapy Myasthenia Gravis - complications Myasthenia Gravis - drug therapy Myasthenia Gravis - therapy Pandemics Plasma Exchange Pneumonia, Viral - complications Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!